Trial reportActa ophthalmologica2026
Long-term follow-up of chronic central serous chorioretinopathy patients receiving oral eplerenone and half-dose photodynamic therapy in the SPECTRA trial: SPECTRA trial report No. 4.
Trial report in Acta ophthalmologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Interventions for central serous chorioretinopathy: a network meta-analysis.The Cochrane database of systematic reviews · 2025Pooled it
- Long-term follow-up of chronic central serous chorioretinopathy patients receiving oral eplerenone and half-dose photodynamic therapy in the SPECTRA trial: SPECTRA trial report No. 4.Acta ophthalmologica · 2026Trial
- Pachychoroid diseases of the macula: an update.Medical hypothesis, discovery & innovation ophthalmology journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeAssessing the 24-month treatment outcome of half-dose photodynamic therapy (PDT) or oral eplerenone in chronic central serous chorioretinopathy (cCSC).
methodsMulticentre randomized clinical trial included cCSC patients from the SPECTRA trial who were randomized to receive half-dose PDT or oral eplerenone. Outcomes were evaluated at 24 months, including the primary outcome measure of complete resolution of subretinal fluid (SRF) on optical coherence tomography (OCT) and the secondary outcome measures best-corrected visual acuity (BCVA), retinal and foveal sensitivity on microperimetry and the National Eye Institute Visual Functioning Questionnaire 25 (NEI-VFQ25) score.
resultsAt baseline, 107 patients were included, of which 80 patients attended the final visit at 24 months: 40 had been randomized to primary treatment with half-dose PDT and 40 to eplerenone. In the eplerenone group, as many as 36/40 (90%) needed crossover treatment at 3 months with half-dose PDT due to persistent SRF, compared to 8/40 (20%) in the half-dose PDT group. At the final visit, complete SRF resolution was observed in 32/40 (80%) who were primarily treated with half-dose PDT and in 35/40 (88%) who received primary eplerenone treatment (p = 0.609). There were no significant differences in terms of BCVA, foveal sensitivity, retinal sensitivity and NEI-VFQ25 score.
conclusionsThis study provides evidence for the long-term efficacy of half-dose PDT in resolving SRF and improving functional outcomes in cCSC. Even when patients initially received eplerenone treatment that did not result in complete SRF resolution, crossover treatment with half-dose PDT led to similar (long-term) group outcomes compared to half-dose PDT as initial treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.